CN110585236A - 植物膜形成的痤疮组合物 - Google Patents
植物膜形成的痤疮组合物 Download PDFInfo
- Publication number
- CN110585236A CN110585236A CN201910413258.7A CN201910413258A CN110585236A CN 110585236 A CN110585236 A CN 110585236A CN 201910413258 A CN201910413258 A CN 201910413258A CN 110585236 A CN110585236 A CN 110585236A
- Authority
- CN
- China
- Prior art keywords
- oil
- extract
- composition
- combination
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 99
- 206010000496 acne Diseases 0.000 title claims abstract description 55
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 50
- 239000012528 membrane Substances 0.000 title description 2
- 208000017520 skin disease Diseases 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 9
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 58
- 239000000284 extract Substances 0.000 claims description 41
- 241000196324 Embryophyta Species 0.000 claims description 40
- 235000019198 oils Nutrition 0.000 claims description 29
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 29
- 229960004889 salicylic acid Drugs 0.000 claims description 29
- 239000003921 oil Substances 0.000 claims description 27
- -1 stearyloxy Chemical group 0.000 claims description 20
- 229920001661 Chitosan Polymers 0.000 claims description 19
- 239000003995 emulsifying agent Substances 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 15
- 235000003880 Calendula Nutrition 0.000 claims description 15
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 14
- 239000000341 volatile oil Substances 0.000 claims description 14
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 150000003751 zinc Chemical class 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000000419 plant extract Substances 0.000 claims description 9
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical group C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 8
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 8
- 229940035437 1,3-propanediol Drugs 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000019502 Orange oil Nutrition 0.000 claims description 8
- 239000010502 orange oil Substances 0.000 claims description 8
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 8
- 239000010679 vetiver oil Substances 0.000 claims description 8
- 229960000541 cetyl alcohol Drugs 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 6
- 239000003974 emollient agent Substances 0.000 claims description 6
- 239000008387 emulsifying waxe Substances 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000010668 rosemary oil Substances 0.000 claims description 6
- 229940058206 rosemary oil Drugs 0.000 claims description 6
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 6
- 235000011399 aloe vera Nutrition 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims description 4
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- 229930002886 farnesol Natural products 0.000 claims description 4
- 229940043259 farnesol Drugs 0.000 claims description 4
- 229930182478 glucoside Natural products 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 229940107702 grapefruit seed extract Drugs 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 3
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 3
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 3
- 244000144927 Aloe barbadensis Species 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 240000001432 Calendula officinalis Species 0.000 claims description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 claims description 3
- 229920000289 Polyquaternium Polymers 0.000 claims description 3
- 244000294611 Punica granatum Species 0.000 claims description 3
- 235000014360 Punica granatum Nutrition 0.000 claims description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 3
- 239000005844 Thymol Substances 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 235000001978 Withania somnifera Nutrition 0.000 claims description 3
- 240000004482 Withania somnifera Species 0.000 claims description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical group [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 3
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 3
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000010619 basil oil Substances 0.000 claims description 3
- 229940018006 basil oil Drugs 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 239000010628 chamomile oil Substances 0.000 claims description 3
- 235000019480 chamomile oil Nutrition 0.000 claims description 3
- 229960003260 chlorhexidine Drugs 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- INSRQEMEVAMETL-UHFFFAOYSA-N decane-1,1-diol Chemical compound CCCCCCCCCC(O)O INSRQEMEVAMETL-UHFFFAOYSA-N 0.000 claims description 3
- 229940073499 decyl glucoside Drugs 0.000 claims description 3
- QIVLQXGSQSFTIF-UHFFFAOYSA-M docosyl(trimethyl)azanium;methyl sulfate Chemical compound COS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C QIVLQXGSQSFTIF-UHFFFAOYSA-M 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000020688 green tea extract Nutrition 0.000 claims description 3
- 229940094952 green tea extract Drugs 0.000 claims description 3
- 229940119170 jojoba wax Drugs 0.000 claims description 3
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000021283 resveratrol Nutrition 0.000 claims description 3
- 229940016667 resveratrol Drugs 0.000 claims description 3
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 3
- 239000001593 sorbitan monooleate Substances 0.000 claims description 3
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 3
- 229950004959 sorbitan oleate Drugs 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 239000010678 thyme oil Substances 0.000 claims description 3
- 229960000790 thymol Drugs 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 235000020334 white tea Nutrition 0.000 claims description 3
- 239000004246 zinc acetate Substances 0.000 claims description 3
- 229960000314 zinc acetate Drugs 0.000 claims description 3
- 235000013904 zinc acetate Nutrition 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 239000011670 zinc gluconate Substances 0.000 claims description 3
- 235000011478 zinc gluconate Nutrition 0.000 claims description 3
- 229960000306 zinc gluconate Drugs 0.000 claims description 3
- 239000011576 zinc lactate Substances 0.000 claims description 3
- 229940050168 zinc lactate Drugs 0.000 claims description 3
- 235000000193 zinc lactate Nutrition 0.000 claims description 3
- 241001116389 Aloe Species 0.000 claims description 2
- 241000086254 Arnica montana Species 0.000 claims description 2
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 241000123069 Ocyurus chrysurus Species 0.000 claims description 2
- 241000750718 Pterocarpus santalinus Species 0.000 claims description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 2
- 239000010653 helichrysum oil Substances 0.000 claims description 2
- 229940069445 licorice extract Drugs 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 claims description 2
- 239000010773 plant oil Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000010677 tea tree oil Substances 0.000 claims description 2
- 229940111630 tea tree oil Drugs 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- GGHMUJBZYLPWFD-UHFFFAOYSA-N patchoulialcohol Chemical compound C1CC2(C)C3(O)CCC(C)C2CC1C3(C)C GGHMUJBZYLPWFD-UHFFFAOYSA-N 0.000 claims 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- 241000208680 Hamamelis mollis Species 0.000 claims 1
- GGHMUJBZYLPWFD-MYYUVRNCSA-N Patchouli alcohol Natural products O[C@@]12C(C)(C)[C@H]3C[C@H]([C@H](C)CC1)[C@]2(C)CC3 GGHMUJBZYLPWFD-MYYUVRNCSA-N 0.000 claims 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims 1
- 229940036350 bisabolol Drugs 0.000 claims 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims 1
- 235000014121 butter Nutrition 0.000 claims 1
- 239000013521 mastic Substances 0.000 claims 1
- 229940118846 witch hazel Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 230000007794 irritation Effects 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 23
- 239000000839 emulsion Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 13
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
- 241000132025 Calendula Species 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 239000012459 cleaning agent Substances 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 229940042129 topical gel Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 244000086363 Pterocarpus indicus Species 0.000 description 4
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229930003658 monoterpene Natural products 0.000 description 3
- 150000002773 monoterpene derivatives Chemical class 0.000 description 3
- 235000002577 monoterpenes Nutrition 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 229930004725 sesquiterpene Natural products 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229940109529 pomegranate extract Drugs 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- SASUFNRGCZMRFD-JCUIILOWSA-N withanolide D Chemical compound C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=C[C@H](O)[C@@]54O[C@@H]5C[C@H]3[C@@H]2CC1 SASUFNRGCZMRFD-JCUIILOWSA-N 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 235000005255 Allium cepa Nutrition 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 101100008153 Arabidopsis thaliana CYTB5-D gene Proteins 0.000 description 1
- 101100008154 Arabidopsis thaliana CYTB5-E gene Proteins 0.000 description 1
- LFYJSSARVMHQJB-UHFFFAOYSA-N Backuchiol Natural products CC(C)=CCCC(C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 235000004101 Gaylussacia dumosa Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical class C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000009604 anaerobic growth Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- LFYJSSARVMHQJB-GOSISDBHSA-N bakuchinol Natural products CC(C)=CCC[C@@](C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-GOSISDBHSA-N 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 229940117895 bakuchiol Drugs 0.000 description 1
- KXXXNMZPAJTCQY-UHFFFAOYSA-N bakuchiol Natural products CC(C)CCCC(C)(C=C)C=Cc1ccc(O)cc1 KXXXNMZPAJTCQY-UHFFFAOYSA-N 0.000 description 1
- CLVIVCIGYFOMLK-UHFFFAOYSA-N benzoyl benzenecarboperoxoate;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 CLVIVCIGYFOMLK-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000001342 boswellia carteri birdw. oil Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000001524 citrus aurantium oil Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000001555 commiphora myrrha gum extract Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- UCYFZDNMZYZSPN-UHFFFAOYSA-N docosyl(trimethyl)azanium Chemical compound CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C UCYFZDNMZYZSPN-UHFFFAOYSA-N 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000010776 emu oil Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010648 geranium oil Substances 0.000 description 1
- 235000019717 geranium oil Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本技术涉及可用于治疗痤疮相关皮肤病的植物膜形成组合物,以及用于治疗这种病症的方法。本发明组合物的优点在于它们可以快速治疗痤疮相关的皮肤病,并且具有最小的刺激和副作用。
Description
技术领域
本技术涉及适用于治疗痤疮相关皮肤病的组合物。
背景技术
痤疮,也称为寻常痤疮,一种皮肤慢性炎性疾病,出现在80%的青少年和年轻人中。它是一种皮肤病,其特征在于,面部、胸部和背部的原发病变,其在皮肤毛孔被油、死皮细胞和细菌堵塞时形成。当皮脂腺过度产生皮脂时,会经常发生痤疮。堵塞的毛孔也会积聚污垢、碎屑和细菌。当阻塞物或堵塞物(粉刺)破裂时,内部的物质会扩散到周围的皮肤。由此产生的皮脂富集的皮肤病易于痤疮丙酸杆菌的厌氧生长,痤疮丙酸杆菌是导致痤疮的主要微生物。此外,表皮葡萄球菌和金黄色葡萄球菌会存在于痤疮病变中。这些微生物(主要是痤疮丙酸杆菌)的增殖导致炎性病变和严重的痤疮。
目前用于减少皮脂产生、疏通毛孔或治疗痤疮的方法包括苛性剂,苛性剂可以进一步导致皮肤刺激或可以导致干燥和片状的皮肤。痤疮也会导致受影响的患者的显著心理发病率。
已经引入了一些治疗来减少由痤疮引起的美学问题和心理问题。目前可用于治疗痤疮的产品包括全身治疗和局部治疗。已发现局部应用治疗剂比激素治疗和激光治疗更可行。目前用于局部治疗的活性剂是视黄酸及其衍生物、过氧化苯甲酰水杨酸以及抗生素。尽管已经注意到水杨酸是所有其它局部药剂中最没有害的药剂,但是继续使用这些药剂会引起不良反应,例如,皮肤刺激、发红和细菌耐药性。此外,某些配方可能需要使用大量的时间,最多6周,以改善皮肤。在局部痤疮治疗中,草药和天然衍生化合物受到关注,因为其似乎比合成药物具有更少的副作用。然而,这些药剂的疗效往往较慢,因此为了实现疗效需要使用高的浓度;而高浓度的药剂可能是有毒。
先前,我们已经基于我们的专利技术(美国专利号7,563,461和7,879,365)开发了含有水杨酸的抗痤疮配方,以治疗痤疮相关的皮肤病。这4步治疗包括每天两次使用清洁剂、爽肤水、乳液和淡斑膏。在4-6周的常规使用期间,这种治疗方法显示出对痤疮皮肤有显著的改善。
然而,研究表明,与目前可获得的大多数竞争性抗痤疮局部用产品一样,4步治疗是耗时的,因此患者可能会不遵守该程序。
因此,一直需要新的和创新的疗法,其快速起作用、来自天然来源、易于使用并且引起最小的刺激。
发明内容
在一些实施方案中,本技术涉及一种适用于治疗痤疮相关皮肤病的组合物,包括:
(a)0.1-1%w/w羟丙基甲基纤维素硬脂氧基醚(疏水改性的羟丙基甲基纤维素)(HPMCSE聚合物);
(b)0.1-1%w/w可溶性锌盐,其中,可溶性锌盐是葡萄糖酸锌、乳酸锌、乙酸锌、柠檬酸锌或上述项的任意组合;
(c)乳化剂,其中,乳化剂包括:(1)0.1-5%w/w下述项中的一种以上:山崳基三甲基硫酸甲酯铵(behentrimonium methosulfate)、十六醇、十八烷醇、丁二醇或十六醇以及丁二醇共混物(称为BTMSCB)或上述项的任意组合;和(2)0.1-5%w/w非离子自乳化蜡(例如PolawaxTM);以及
(d)0.5-2%w/w水杨酸,或0.5-10%w/w过氧化苯甲酰,或上述项的组合。
在其他实施方案中,本文的组合物还包括例如0.1-1%的壳聚糖;以及例如0.1-3%的纤维素聚合物,例如,羟乙基纤维素、羟丙基甲基纤维素、甲基纤维素、聚季铵盐10或上述项的任意组合。
在其他实施方案中,本文的组合物还包括例如含量为0.1-20%或0.1-2%的金盏花油或提取物,或例如含量为0.1-5%、0.1-50%的芦荟凝胶或提取物,或者上述项的任意组合。
在其他实施方案中,本文的组合物还包括含量为例如0.5-10%w/w的润肤剂溶剂,其中,润肤剂溶剂是1,3-丙二醇(例如,可以获得自美国田纳西州劳登有限责任公司的杜邦泰莱生物制品公司的商品名)、甘油、辛酰基癸酰基甘油三酯(caprylil capryltriglyceride)、丁二醇、辛二醇、癸二醇、苯甲醇、乙基己基甘油、法呢醇或上述项的任意组合。
在其他实施方案中,本文的组合物还包括植物;在各种实施方案中,植物可以是例如橙油、0.05-0.2%w/w的迷迭香油、0.01-0.1%w/w的香根草油、0.01-0.1%w/w的紫檀粉末或提取物、0.2-1%w/w石榴油或提取物、0.3-1%w/w的葡萄柚籽提取物、0.3-1%w/w柠檬提取物、0.2-3%w/w的茶树油、0.2%-2%w/w的山金车油、0.2-2%w/w的甘草提取物、0.2-2%w/w的乳香油、0.01-2%w/w蜡菊油、0.01-2%w/w的天竺葵油、0.01-2%w/w的没药油、0.01-2%w/w的橙花油、0.01-1%w/w的睡茄花(Withania somnifera flower)提取物、0.01至1%w/w的曼吉萨(manjistha)(茜草)提取物、0.5-5%的洋葱提取物,或上述项的任意组合。
在各种实施方案中,本文的组合物包括各自含量为0.1-1%的乙醇酸、乳酸、苯甲酸或上述项的组合,即总可能量为3%的这种酸。
在其他实施方案中,本文的组成进一步包含附加成分,包括但不限于:溶剂或增溶剂;表面活性剂水、醇、脱水山梨糖醇单月桂酸酯(例如,20)、脱水山梨糖醇单油酸酯(例如,80)、脱水山梨糖醇油酸酯癸基葡糖苷、脱水山梨糖醇糖(例如,mulse)、辛酰基癸酰基葡糖苷(caprylil capryl glucoside)、PEG 40氢化蓖麻油、三癸-9丙二醇(例如,增溶剂660352)、椰油酰胺丙基甜菜碱、水或上述项的任意组合。
在其他实施方案中,本文的组合物还包括精油或精油组分(成分),或植物提取物,包括但不限于:薰衣草油、洋甘菊油、罗勒油、百里香油、麝香草酚、薄荷醇、橙油、香根草油、补骨脂油、荷荷巴油、椰子油、太阳花油、红花油、杏仁油、蜂蜜、白茶提取物、绿茶提取物、白藜芦醇或上述项的任意组合。
在其他实施方案中,本文的组合物还包括含量例如为0.1-1%的防腐剂。在各种实施方案中,防腐剂是氯己定(例如,葡萄糖酸氯己定)、苯扎氯铵、苯氧基乙醇、苯基乙醇或上述项的任意组合。
在其他实施方案中,本文的组合物还包括抗氧化剂,例如维生素E、维生素C或上述项的任意组合。
在其他实施方案中,本技术涉及治疗痤疮相关的皮肤病的方法,包括将本文所述的任一种组合物与皮肤接触。
在其他实施方案中,本技术涉及治疗痤疮相关皮肤病的方法,包括以下步骤:
(a)将可溶性锌盐、芦荟粉、乳酸和乙醇酸溶于50至60℃的水中;
(b)任选地加入增稠剂或表面活性剂;
(c)添加乳化剂并搅拌至溶解,乳化剂包括山崳基三甲基硫酸甲酯铵、十六醇和丁二醇(BTMSCB)以及非离子自乳化蜡;
(d)使混合物冷却至30至40℃;
(e)加入HPMCSE聚合物凝胶、壳聚糖凝胶和金盏花提取物;
(f)混合以得获得乳脂状凝胶(相A);
(g)使水杨酸和一种或多种植物提取物或油在溶剂中结合,并混合(相B);
(h)将相A和相B结合以获得痤疮组合物;以及
(i)使痤疮组合物与皮肤接触。
具体实施方式
除非另有说明,否则本文中表示的所有百分比均以重量计。
在某些实施方案中,本文的技术涉及使用含有水杨酸和植物药的成膜凝胶治疗与痤疮相关的皮肤病的2步治疗。
如本文所用,术语“痤疮相关的皮肤病”和“与痤疮相关的皮肤病”可互换并且是指由死皮细胞、细菌或干皮脂积聚引起的任何皮肤疾病,所述积聚阻塞皮肤中的毛囊或导致黑头(开放性黑头)、白头(封闭性黑头)、丘疹(丘疹)、囊肿或皮肤凹陷。
如本文所用,“精油”(EO)是从植物或动物来源获得的挥发性油,其包括一种或多种活性剂(在本文中也称为分离组分或“IC”或“组分”或“成分”),例如但不限于,单萜烯或倍半萜烯烃、醇、酯、醚、醛、酮或氧化物。精油通常通过蒸馏、表达、萃取、树脂攻丝、蜡嵌入或冷压提取。分离的组分通常分为以下类别:酸、醇(例如,单萜烯醇或倍半萜烯醇)、醛、香豆素、酯、酮、内酯、萜烯(例如,单萜烯或倍半萜烯)、氧化物或酚。
在整个本发明中,当提及天然(植物或动物)油源时,例如“柠檬油”或“鸸鹋油”,这表示与称之为精油相同的事物;但是精油不可商购的情况除外,使用绝对油。
如本文所用的那样,“植物提取物”是指来自植物来源(植物)的组合物,其通过将植物浸泡在溶剂(例如水或醇)中制备。植物提取物是指产生的液体,其包括含有精油的溶剂。如本文的实施方案和数据中所述,术语“(100%/油)”表示100%提取物或油。
在局部痤疮治疗中,植物药和天然衍生化合物已经受到相当大的关注,因为它们具有比合成药剂更少的副作用。然而,这些药剂是缓慢作用的,因此需要高浓度才能有效,然而高浓度的药剂可能是有毒的。我们早期对植物药的研究表明,植物药和合成药的联合治疗比使用单一产品灭活细菌更有效。
我们描述了用于治疗轻度和中度痤疮的独特成膜凝胶的发展,该独特成膜凝胶包括锌、水杨酸和植物药(FGZB)配方。
在某些实施方案中,FGZB包括组合上具有变化和治疗性质的成分。本文所述的独特组合物可以抑制导致许多病症的微生物的生长,所述病症包括痤疮、瘙痒、红斑和鳞屑。该组合物还可以使得丘疹和脓疱数量的减少;并且还可以有效控制皮脂分泌。另外,在某些实施方案中,本文的组合物可以在皮肤上保留更长的时间并且在施用时将活性物质连续释放到皮肤中。
在某些实施方案中,配方中的抗菌活性物质是一种或多种植物药和水杨酸的组合。除其他特征外,这种独特的技术可以:(i)增强水杨酸的抗菌功效;(ii)滋润皮肤而不是干燥和刺激皮肤,同时保持不油腻,(iii)在皮肤上形成持久的阻隔膜,从而防止刺激物和细菌通过,并且同时灭活导致痤疮的皮肤细菌病变。
在某些实施方案中,本文的组合物包括一种或多种以下成分(依次对各个成分进行描述):
(a)0.1-1%w/w的羟丙基甲基纤维素硬脂氧基醚。这是疏水改性的羟丙基甲基纤维素聚合物(HPMCSE聚合物),其可以在水中形成独特的膜形成疏水/亲水凝胶,并且在施用时可以在皮肤上提供丝般光滑的感觉。
(b)0.1-1%的可溶性锌盐。示例性锌盐包括葡萄糖酸锌、乳酸锌、乙酸锌、柠檬酸锌以及上述项的组合。锌盐具有抗刺激性和抗炎性,当与成膜HPMCSE聚合物结合时形成含锌的屏障基质,该屏障基质可以使蛋白质沉淀在炎性丘疹和脓疱中,因此可以减小它们的大小和外观。此外,该基质可以防止刺激物和细菌通过,同时灭活引起痤疮损伤的皮肤细菌。
(c)0.1-5%的乳化剂。这些乳化剂可以包括以下任意一种:1)BTMSCB,其是behentrimonium methosulfate(和)十六醇(和)丁二醇的共混物,是一种温和(elegant)的蔬菜基调理乳化剂;或2)0.1至3%的非离子自乳化蜡,例如通过品牌名称PolawaxTM可获得和从克罗达公司(英国东约克郡斯奈斯)可获得的那些乳化剂。其他乳化剂包括可以从丽塔公司(美国伊利诺伊州水晶湖)的品牌名称可获得的那些乳化剂,以及从UnivearSolutions(美国伊利诺伊州唐纳斯格罗夫)的品牌名称可获得的聚季铵盐乳化剂。在某些实施方案中,该组合物包括总共0.2-10%w/w的乳化剂,例如,0.1-5%的上述1)的选项,和0.1-5%的上述2)的非离子自乳化蜡。
在某些实施方案中,已发现在配方中组合使用成分a、b、c产生稳定的成膜凝胶(FGZ),其是非粘性的、不油腻的、具有润肤和保湿性质。当将活性成分例如水杨酸和植物药掺入FGZ中并施用于皮肤上时,活性成分以持续的方式长时间释放、抑制细菌生长并减少痤疮相关的皮肤病。
(d)0.2-2%的α羟基酸,例如,水杨酸、乳酸、乙醇酸或上述项的任意组合,其可以帮助皮肤的顶层再生或剥离、去除死皮细胞和疏通毛孔,从而防止病变,并使得能够形成新透明皮肤。
在某些实施方案中,含有水杨酸的FGZ还可包括以下(1)-(9)中的任一种:
(1)1%的壳聚糖,壳聚糖是一种具有抗菌和伤口愈合性能的天然成膜多糖聚合物;
(2)0.1-3%的纤维素聚合物(其可以充当增稠剂),纤维素聚合物可以包括以下项中的任一项:羟乙基纤维素、羟丙基甲基纤维素(例如,以品牌名称MethocelTM出售并且可以从密歇根州米德兰的陶氏化学公司获得)、甲基纤维素、聚季铵盐10(季铵化羟乙基纤维素)、羟丙基甲基纤维素硬脂氧基醚(例如,以品牌名称出售,并且可以从日本大阪大同化工公司获得),或上述项的任意组合;
(3)植物共混物,可以包括以下项中的任一种:迷迭香油(0.05-0.2%)和香根草油(0.01-0.1%)、紫檀香膏/提取物(0.01-0.1%)、橙油(0.1-0.5%)、基于植物的1,3-丙二醇(1-10%)、苯甲醇(0.5-2%)及上述项的任意组合。当用于FGZ+水杨酸配方时,这种植物共混物可以增强抗菌活性并减少皮肤刺激;
(4)0.1-0.5%或0.1-5%的金盏花油或提取物、0.1-0.5%或0.1-5%的芦荟凝胶或提取物或上述项的组合,其减轻炎症,舒缓皮肤,缓解瘙痒、刺激和灼烧感;
(5)0.3-7%的润肤剂溶剂,其可以是以下项中的任一种:1,3丙二醇、甘油、辛酰基癸酰基甘油三酯、丁二醇、辛二醇、癸二醇、苯甲醇、乙基己基甘油、法呢醇或其任意组合。
(6)一种或多种α-羟基酸或果酸,可以是以下项中的任一种:乙醇酸、乳酸、苯甲酸或上述项的任意组合;
(7)一种或多种精油或植物提取物,或其成分(即,精油或植物提取物的成分),其可以是以下项中的任一种:石榴油或提取物(0.3-1%)、葡萄柚籽提取物(0.3-1%)、薰衣草油、洋甘菊油、罗勒油、百里香油、麝香草酚、薄荷醇、法尼醇、补骨脂酚、葡萄柚籽提取物、荷荷巴油、白茶提取物、绿茶提取物、白藜芦醇或上述项的任意组合。这些成分具有抗菌和抗炎特性;
(8)一种或多种溶剂,例如,水、醇、脱水山梨糖醇单月桂酸酯(例如,20)、脱水山梨糖醇单油酸酯(例如,80)、脱水山梨糖醇油酸酯癸基葡糖苷、脱水山梨糖醇糖(例如,mulse)、辛酰基癸酰基葡糖苷、PEG 40氢化蓖麻油、三癸-9丙二醇(例如,增溶剂660352)、Peg 40氢化蓖麻油、三癸-9、水的共混物(例如,增溶剂611674)。
(9)防腐剂(0.1-1%),例如氯己定、苯扎氯铵、苯氧基乙醇、苯基乙醇或上述项的任意组合。
在各种实施方案中,本文的组合物可包括下述多种附加成分中的任一种,包括但不限于以下:视黄醇(也称为维生素A1),或视黄醇的天然替代物,例如通过Sytheon有限公司(美国新泽西州布顿市)的商标获得的巴库硫醇化合物;一种或多种泊洛沙姆,即由聚氧丙烯(聚(环氧丙烷)链的中心疏水链组成的非离子三嵌段共聚物,两侧有两条亲水性聚氧乙烯链(聚(环氧乙烷)),其可以通过巴斯夫公司(德国路德维希港)的品牌名称获得;抗刺激性或抗瘙痒或抗组胺化合物,例如,通过Symreise股份公司(德国Holzminden)的品牌名称可获得的合成芳胺;维生素,不论是否被认为是抗氧化剂,例如维生素A、维生素C、维生素E或维生素B,例如,通过丽塔公司(美国伊利诺伊州水晶湖)的品牌名获得的维生素B-5前化合物;或增稠剂,例如,通过克罗达个人护理(斯奈斯,东约克郡,英国)的品牌名incromineTM可获得的一种增稠剂;或美发成分,例如通过克罗达个人护理公司(英国东约克郡斯奈斯)品牌名IncroquatTM Behenyl TMS可获得的美发成分。
实施例1
稳定FGZB配方的开发
制备以下配方,这些配方包括不同量的乳化剂、HPMCSE聚合物(S)、壳聚糖(C)及上述项的组合。评价这些配方的成膜性和稳定性。
配方样品EC
成分
%(w/w)
水杨酸 2
基础成分
配方样品SC
成分 %(w/w)
水杨酸 2
基础成分
配方样品SE-1
成分 %(w/w)
水杨酸 2
基础成分
配方样品SE-2
成分 %(w/w)
水杨酸 2
基础成分
配方样品SCE-1
成分 %(w/w)
水杨酸 2
基础成分
葡萄糖酸氯己定 0.05
配方样品SCE-2
成分 %(w/w)
水杨酸 2
基础成分
配方在40℃下7天的稳定性如下所示:
结论:从上述图中可以看出,只有HpMCSE聚合物(S)、乳化剂和Chitosan(SCE)的配方导致凝胶均匀。SE-2配方中S为0.7%,乳化剂(5.5%)也得到均匀凝胶。
而Se(S)为0.5%(S)和乳化剂(5.5%),乳化剂和壳聚糖EC,SC和Chitosan分离,未形成均匀的凝胶。
还制备了各种SCE配方,其中S浓度在0.1%-1%w/w,C浓度在0.1%-0.5%w/w,E浓度在0.4%-5%w/w之间,并发现其稳定。
实施例2
水杨酸与植物药联合应用的抗菌效果
在FGZ凝胶中混合各种植物、水杨酸和组合,并评价抗菌效果。结果如下表所示。
表1水杨酸和植物药在FGZ碱中的抗菌活性(抑制区试验)
表1
“植物共混物”包括:石榴提取物(0.5%)、迷迭香油(0.1%)、橙油(0.2%)、香根草油(0.02%)、紫檀提取物(0.1%)、植物基苯甲醇(1%)、植物基1,3丙二醇(2%)。
结论:植物共混物协同增强水杨酸的功效。
表2抗菌活性(杀灭试验菌金黄色葡萄球菌的快速性)
ASTM-E2783-1198751-1(悬浮试验)中描述的快速压井(15秒)试管法。
根据ASTM E2783-11进行体外快速杀灭试验,在TSA培养基中制备108cfu ml-1微生物培养基,以测定痤疮配方的抗菌活性。0.9毫升痤疮配方与0.1毫升微生物培养物接触15秒,然后用去离子剂中和。PBS被用作对照。在本研究中,如果log10减少量达到3.0或更高,则认为痤疮产品有效。
表2
植物共混物1包括:迷迭香油(0.1%)、橙油(0.2%)、香根草油(0.02%)、紫檀提取物(0.1%)、苄醇(1%)、植物基1,3丙二醇(2%)。
植物共混物2包括:石榴提取物(0.5%)、迷迭香油(0.1%)、橙油(0.2%)、香根草油(0.02%)、紫檀提取物(0.1%)、苄醇(1%)、植物基1,3丙二醇(2%)。
结论:植物共混物与水杨酸组合显示出更高的抗菌功效。
实施3
含有水杨酸和植物药(FGZB)的各种SCE-锌盐膜(FGZ)配方,例如:如下制备清洁剂、乳液和斑点霜,并且发现它们是稳定且有效的。
HGZB清洁剂C-7
相A(50-60)
相B植物共混物
HGZB清洁剂C-8
相A(50-60)
相B植物共混物
HGZB清洁剂F-3 pH4.5
HGZB清洁剂F-4 pH 4.5
HGZB清洁剂F-5 pH 4.5
HGZB清洁剂F-7 pH4.0
HGZB清洁剂F-8 pH 4.0
HGZB清洁剂F-9 pH 4.0
HGZB清洁剂F-13 pH4.0
HGZB清洁剂F-14 pH 4.0
HGZB清洁剂F-15 pH 4.0
HGZB清洁剂F-16 pH 4.0
FGZB乳液G-1
相A(50-60)
相B
90L 1% 50
将相B添加到相A
总相A+B 83.7
相C植物共混物
FGZB乳液G-3
相A(50-60)
相B
90L 1% 52
将相B添加到相A
壳聚糖3% 10
金盏花提取物(100%/油) 1
总相A+B 85.33
相C植物共混物
FGZB乳液G-3A
相A(50-60)
相B
90L 1% 52
将相B添加到相A
壳聚糖3% 10
金盏花提取物(100%/油) 1
总相A+B 85.33
相C植物共混物
FGZB乳液G-3B
相A(50-60)
冷却至30-40℃
相B
90L 1% 52
将相B添加到相A
壳聚糖3% 10
金盏花提取物(100%/油) 1
总相A+B 85.33
相C植物共混物
FGZB乳液G-3C
相A(50-60)
相B
90L 1% 52
将相B添加到相A
壳聚糖3% 10
金盏花提取物(100%/油) 1
总相A+B 84.24
相C植物共混物
FGZB乳液G-4
相A(50-60)
相B
90L 1% 52
将相B添加到相A
壳聚糖3% 10
金盏花提取物(100%/油) 1
总相A+B 84.33
相C植物共混物
FGZB乳液G-5A
FGZB乳液G-6
FGZB乳液G-7
FGZB乳液G-8
FGZB乳液G-8M
pH 4.6
FGZB乳液G-11
FGZB乳液G-12
FGZB乳液G-19
FGZB乳液G-20
Z透明祛痘乳液G-21
FGZB乳液G-22
FGZB斑点凝胶B2
相A(50-60)
相B植物共混物
FGZB斑点凝胶B3局部用凝胶剂
FGZB斑点凝胶B4局部用凝胶剂
FGZB斑点凝胶B5局部用凝胶剂
相A(50-60)
相B
90L 1% 52
将相B添加到相A
甲壳胺3% 10
金盏花提取物(100%/油) 1
总相A+B 83.83
相C植物共混物
FGZB斑点凝胶B5-A局部用凝胶剂
相A(50-60)
相B
90L 1% 52
将相B添加到相A
壳聚糖3% 10
金盏花提取物(100%/油) 1
总相A+B 84.83
相C植物共混物
FGZB斑点凝胶B5-B局部用凝胶剂
相A(50-60)
相B
90L 1% 52
将相B添加到相A
甲壳胺3% 10
金盏花提取物(100%/油) 1
总相A+B 85.33
相C植物共混物
FGZB斑点凝胶B6局部用凝胶剂
相A(50-60)
相B
90L 1% 52
将相B添加到相A
壳聚糖3% 10
金盏花提取物(100%/油) 1
总相A+B 83.83
相C植物共混物
FGZB斑点凝胶B6-A局部用凝胶剂
相A(50-60)
相B
90L 1% 52
将相B添加到相A
壳聚糖3% 10
金盏花提取物(100%/油) 1
总相A+B 84.83
相C植物共混物
FGZB斑点凝胶B6-B局部用凝胶剂
相A(50-60)
相B
90L 1% 52
将相B添加到相A
壳聚糖3% 10
金盏花提取物(100%/油) 1
总相A+B 85.33
相C植物共混物
FGZB斑点凝胶B7局部用凝胶剂
相A(50-60)
相B
90L 1% 52
将相B添加到相A
壳聚糖3% 10
金盏花提取物(100%/油) 1
总相A+B 84.83
相C植物共混物
FGZB斑点凝胶SP-9
pH 4.0
FGZB斑点凝胶SP-11
pH 4.0
FGZB斑点凝胶SP-12
pH 4.0
FGZB斑点凝胶SP-13
pH 4.0
FGZB斑点凝胶SP-14
pH 4.3
FGZB斑点凝胶SP-15
pH 4.3
FGZB斑点凝胶SP-16
pH 4.3
FGZB斑点凝胶BSP-1
pH 4.3
FGZB斑点凝胶BSP-2
pH 4.3
FGZB疤痕去除血清
FGZB去角质擦拭液
去角质擦拭液-EW3
去角质擦拭液-EW4
去角质擦拭液-EW5
去角质擦拭液-EW6
去角质擦拭液-EW7
去角质擦拭液-EW7B
急性去疤霜
实施例4
FGZB斑点凝胶和其他含有锌盐,植物和水杨酸痤疮霜1和水杨酸痤疮霜2的斑点凝胶配方的抗菌功效比较
痤疮霜1
成分 %WT
水杨酸(活性) 2%
基础成分
痤疮霜2
FGZB B-2外用凝胶
表3FGZB-B2点霜对金黄色葡萄球菌的抗菌功效:与含水杨酸的其他痤疮霜产品比较
表3
结论:FGZB-1显示出对金黄色葡萄球菌的更大抑制区,金黄色葡萄球菌也是出现痤疮粉刺的原因。
表4治疗7至10天后,FG ZB-B2对2名受试者的功效
表4
结果显示,治疗仅7至10天后,痤疮症状减少50%至100%。有利地,在任一志愿者中均未报告出现瘙痒和/或灼烧感。
已经显示含有水杨酸的配方在4-6周内改善痤疮影响的皮肤。我们的初步评估表明,FGZB在7-10天内显示出受痤疮影响的皮肤得到改善。
尽管已经接合本发明的实施方案描述了本发明,但是这些实施方案和示例仅仅是示例性的而非限制性的。对于本领域技术人员而言,许多其他变化和修改以及其他用途将变得显而易见。因此,本发明不应受本文具体公开的限制,并且可以在不脱离其精神的情况下通过未在此明确描述的其他形式实施。
Claims (13)
1.一种适用于治疗痤疮相关皮肤病的组合物,包括:(a)0.1-1%w/w羟丙基甲基纤维素硬脂氧基醚(疏水改性的羟丙基甲基纤维素)(HPMCSE聚合物);
(b)0.1-1%w/w可溶性锌盐,其中,所述可溶性锌盐是葡萄糖酸锌、乳酸锌、乙酸锌、柠檬酸锌或上述项的任意组合;(c)0.1-5%w/w乳化剂,其中,所述乳化剂包括:(1)0.1-5%w/w下述项中的一种以上:山崳基三甲基硫酸甲酯铵、十六醇、十八烷醇、丁二醇或十六醇以及丁二醇共混物(称为BTMSCB)或上述项的任意组合;(2)0.1-5%w/w非离子自乳化蜡;以及
(d)0.5-2%w/w水杨酸,或0.5-10%w/w过氧化苯甲酰,或上述项的组合。
2.根据权利要求1所述的组合物,还包括0.1-1%w/w的壳聚糖。
3.根据权利要求1所述的组合物,还包括0.1-3%的纤维素聚合物,其中,所述纤维素聚合物是羟乙基纤维素、羟丙基甲基纤维素、甲基纤维素、聚季铵盐10或上述项的任意组合。
4.根据权利要求1所述的组合物,还包括0.1-2%的金盏花油或提取物,或0.1-5%的芦荟凝胶或提取物,或上述项的任意组合。
5.根据权利要求1所述的组合物,还包括0.5-10%w/w的润肤剂溶剂,其中,所述润肤剂溶剂是1,3-丙二醇、甘油、辛酰基癸酰基甘油三酯、丁二醇、辛二醇、癸二醇、苯甲醇、乙基己基甘油、法呢醇或上述项的任意组合。
6.根据权利要求1所述的组合物,还包括植物,其中,所述植物是橙油、0.05-0.2%w/w的迷迭香油、0.01-0.1%w/w的香根草油、0.01-0.1%w/w的紫檀香膏或提取物、0.2-1%w/w的石榴油或提取物、0.3-1%w/w的葡萄柚籽提取物;0.3-1%w/w的柠檬提取物、0.2-3%的茶树油、0.2-2%w/w的山金车油、0.2-2%w/w的甘草提取物、0.2-2%的乳香油、0.01-2%w/w的蜡菊油、0.01-1%w/w的睡茄花提取物、0.01-1%w/w的曼吉萨(茜草)提取物或上述项的任意组合。
7.根据权利要求1所述的组合物,还包括各自含量为0.1-1%的乙醇酸、乳酸、苯甲酸或上述项的组合。
8.根据权利要求1所述的组合物,还含有0.5-15%的附加成分,其中,所述附加成分是以下项中的一种或多种:溶剂或增溶剂;表面活性剂水、醇、脱水山梨糖醇单月桂酸酯、脱水山梨糖醇单油酸酯、脱水山梨糖醇油酸酯癸基葡糖苷、脱水山梨糖醇糖、辛酰基癸酰基葡糖苷、PEG40氢化蓖麻油、三癸-9丙二醇、椰油酰胺丙基甜菜碱、水或上述项的任意组合的共混物。
9.根据权利要求1所述的组合物,还含有精油或精油组分,或植物提取物;其中,所述精油或精油组分或植物提取物是薰衣草油、洋甘菊油、罗勒油、百里香油、麝香草酚、薄荷脑、橙油、香根草油、补骨脂醇、荷荷巴油、白茶提取物、绿茶提取物、金缕梅提取物、红没药醇、白藜芦醇或上述项的任意组合。
10.根据权利要求1所述的组合物,还包括0.1-1%的防腐剂,其中,所述防腐剂是氯己定、苯扎氯铵、苯氧基乙醇、苯基乙醇或上述项的任意组合。
11.根据权利要求1所述的组合物,还包括0.1-1%的抗氧化剂,其中,所述抗氧化剂是维生素E、维生素C或上述项的任意组合。
12.一种治疗痤疮相关皮肤病的方法,包括将权利要求1所述的组合物与皮肤接触。
13.一种治疗痤疮相关皮肤病的方法,包括以下步骤:
(a)将可溶性锌盐、芦荟粉、乳酸和乙醇酸溶于50至60℃的水中;
(b)任选地加入增稠剂或表面活性剂;(c)添加乳化剂并搅拌至溶解,所述乳化剂包括山崳基三甲基硫酸甲酯铵、十六醇和丁二醇(BTMSCB)和非离子自乳化蜡;
(d)使混合物冷却至30至40℃;(e)加入HPMCSE聚合物凝胶、壳聚糖凝胶和金盏花提取物;
(f)混合以得获得乳脂状凝胶(相A);
(g)使水杨酸和一种或多种植物提取物或油在溶剂中结合,并混合(相B);
(h)将相A和相B结合以获得痤疮组合物;以及
(i)使所述痤疮组合物与皮肤接触。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862684030P | 2018-06-12 | 2018-06-12 | |
US62/684,030 | 2018-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110585236A true CN110585236A (zh) | 2019-12-20 |
Family
ID=68765392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910413258.7A Pending CN110585236A (zh) | 2018-06-12 | 2019-05-17 | 植物膜形成的痤疮组合物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20190374573A1 (zh) |
EP (1) | EP3806843A1 (zh) |
CN (1) | CN110585236A (zh) |
BR (1) | BR112021001112A2 (zh) |
CA (1) | CA3106075A1 (zh) |
WO (1) | WO2019240908A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112603993A (zh) * | 2020-12-19 | 2021-04-06 | 江苏诺瓦立医疗用品有限公司 | 一种基于壳聚糖治疗炎性痤疮的凝胶及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113180066A (zh) * | 2021-05-08 | 2021-07-30 | 宁波帕柯斯新材料科技有限公司 | 一种高浓缩缓释抑菌水剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101778620A (zh) * | 2007-05-22 | 2010-07-14 | 捷通国际有限公司 | 紧实和提拉皮肤的组合物及使用方法 |
US7951840B2 (en) * | 2002-02-07 | 2011-05-31 | Modak Shanta M | Zinc salt compositions for the prevention of dermal and mucosal irritation |
US20120058061A1 (en) * | 2009-03-09 | 2012-03-08 | Coty Germany Gmbh | Cosmetic basic composition and its use |
CN104994878A (zh) * | 2012-12-13 | 2015-10-21 | 纽约市哥伦比亚大学理事会 | 植物抗微生物组合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020078709A (ko) * | 2001-04-10 | 2002-10-19 | (주) 바임래버러토리즈 | 여드름 치료용 조성물 및 그 제조방법 |
US7563461B2 (en) * | 2002-02-07 | 2009-07-21 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
WO2008133822A1 (en) * | 2007-04-27 | 2008-11-06 | The Backdoor Salon, Inc. | Skin care composition |
US9511040B2 (en) * | 2007-06-20 | 2016-12-06 | The Trustees Of Columbia University In The City Of New York | Skin and surface disinfectant compositions containing botanicals |
DE102007029735A1 (de) * | 2007-06-25 | 2009-01-08 | Beiersdorf Ag | Copolymer mit wasserlöslichen Lipiden |
WO2010109420A1 (en) * | 2009-03-25 | 2010-09-30 | Sulur Subramaniam Vanangamudi | A medicinal anti acne cream comprising chitosan and a process to make it |
US20130230609A1 (en) * | 2012-03-05 | 2013-09-05 | Shanta Modak | Antimicrobial/preservative compositions comprising botanicals |
MA39727A (fr) * | 2014-03-10 | 2017-01-18 | Univ Columbia | Compositions antimicrobiennes pour végétaux |
-
2019
- 2019-05-17 BR BR112021001112A patent/BR112021001112A2/pt unknown
- 2019-05-17 US US16/415,339 patent/US20190374573A1/en not_active Abandoned
- 2019-05-17 CA CA3106075A patent/CA3106075A1/en not_active Abandoned
- 2019-05-17 EP EP19820630.2A patent/EP3806843A1/en not_active Withdrawn
- 2019-05-17 WO PCT/US2019/032832 patent/WO2019240908A1/en unknown
- 2019-05-17 CN CN201910413258.7A patent/CN110585236A/zh active Pending
-
2021
- 2021-02-18 US US17/178,692 patent/US20210346425A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7951840B2 (en) * | 2002-02-07 | 2011-05-31 | Modak Shanta M | Zinc salt compositions for the prevention of dermal and mucosal irritation |
CN101778620A (zh) * | 2007-05-22 | 2010-07-14 | 捷通国际有限公司 | 紧实和提拉皮肤的组合物及使用方法 |
US20120058061A1 (en) * | 2009-03-09 | 2012-03-08 | Coty Germany Gmbh | Cosmetic basic composition and its use |
CN104994878A (zh) * | 2012-12-13 | 2015-10-21 | 纽约市哥伦比亚大学理事会 | 植物抗微生物组合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112603993A (zh) * | 2020-12-19 | 2021-04-06 | 江苏诺瓦立医疗用品有限公司 | 一种基于壳聚糖治疗炎性痤疮的凝胶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20190374573A1 (en) | 2019-12-12 |
US20210346425A1 (en) | 2021-11-11 |
WO2019240908A1 (en) | 2019-12-19 |
CA3106075A1 (en) | 2019-12-19 |
EP3806843A1 (en) | 2021-04-21 |
BR112021001112A2 (pt) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080045491A1 (en) | Surface sanitizer | |
CN110035797B (zh) | 用于治疗痤疮的具有益生元特性的协同草药组合物 | |
EP2961418B1 (en) | Acne solution | |
US20210346425A1 (en) | Botanical film-forming acne compositions | |
JP2693859B2 (ja) | 尋常性▲ざ▼瘡用皮膚外用剤 | |
US11564963B2 (en) | Topical compositions, process of large-scale manufacture, and method of use | |
CN114796038A (zh) | 一种快速祛痘杀菌除螨组合物及其制备方法和应用 | |
JP4414495B2 (ja) | 抗菌剤、並びにそれを含む皮膚外用剤及び皮膚洗浄剤 | |
CN113456570A (zh) | 一种祛痘组合物、祛痘啫喱及其制备方法 | |
WO2004105689A2 (en) | Topical composition for the treatment of skin disorders and methods of using the same | |
KR20150112439A (ko) | 여드름 예방 및 치료용 약학적 조성물, 피부 외용제 및 꽃범의 꼬리 추출물의 추출 방법 | |
JPS62126128A (ja) | 抗菌剤 | |
JP6856642B2 (ja) | 皮膚軟化組成物 | |
JP2024517225A (ja) | 皮膚症状を治療するためのマヌカオイルおよびパルマローザオイルを含有する局所用組成物 | |
JP2819033B2 (ja) | プロピオニバクテリウムアクネスの発育阻害剤を含有する皮膚又は頭髪用外用剤、又は化粧料 | |
KR100892742B1 (ko) | 여드름 치료용 피부 외용제 조성물 | |
CN107157846A (zh) | 一种祛痘护肤面膜 | |
US9556138B2 (en) | Method of treatment for acne and an anti-acne formulation | |
GB2441599A (en) | Herbal composition and method for the treatment of skin disorders and fungal infections thereof | |
US11458183B1 (en) | Inducing granulation tissue in third-degree skin burns using topical Hamelia patens extract | |
BR102022006318A2 (pt) | Preparação medicinal à base de óleos essenciais para tratamento, prevenção e controle de mastite em animais | |
BR102021009954A2 (pt) | Composição dermofitocosmética a base do extrato das folhas de cochlospermum regium (schrank) pilger em combinação com o extrato da entrecasca de myracrodruon urundeuva all | |
US20150209401A1 (en) | Synergistic Multi-Active Composition for Topical Treatment of Disorders in Mammals, Use of Composition, and Method | |
Yürekli | Tea Tree Oil in Dermatology | |
Chubinidze et al. | On The Issue of Treatments of Acne. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40019533 Country of ref document: HK |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191220 |
|
WD01 | Invention patent application deemed withdrawn after publication |